Parkinson's Disease Dementia
A Study of LY3154207 in Participants With Parkinson's Disease (Part B)
The purpose of part B of this study will evaluate how safe LY3154207 is and the effect it has on the body.
The results of this study are not yet available.
Your participation could last up to 49 weeks including a 17 day stay in the clinical research unit (CRU) and follow-up.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Part B participant must have a clinical diagnosis of Parkinson's disease for at least 1 year and be on stable medication for at least 4 weeks
Part B participant must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Part B participant must not have participated in a clinical trial involving an investigational product within the last 30 days
Part B participant must provide written informed consent